As younger patients remain in the hospitals with COVID-19, Pfizer and BioNTech announced that children ages 5-11 can soon expect a vaccine to be ready for them. 

In a press release on Sept. 20, Pfizer said  Phase 2 of 3 of their trial showed children receive antibodies from a lower dose of the vaccine. This is a dose considered to be safe for their age.

“Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine. We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children,” said Albert Bourla, chairman and chief executive officer of Pfizer in a press release. 

As the delta variant surged across the United States, more children were infected with COVID-19. According to the Springfield-Greene County Health Department, those aged newborns through age 11 had a spike in COVID-19 cases in July 2021

“We are pleased to be able to submit data to regulatory authorities for this group of school-aged children before the start of the winter season,” said Dr. Ugur Sahin, CEO and co-founder of BioNTech in a press release. “The safety profile and immunogenicity data in children aged 5 to 11 years vaccinated at a lower dose are consistent with those we have observed with our vaccine in other older populations at a higher dose.”

For more information on who can get vaccinated see the Springfield-Greene County Health Department’s website at

Follow Desiree Nixon on Twitter, @DesireeNixon17

Subscribe to The Standard's free weekly newsletter here.